The Israeli that soared on Wall Street following an experiment in the treatment of brain cancer

As a result, the company is trading at a value of 400 million dollars. The company’s stock has already completed increases of about 50% compared to the minimum recorded about a year ago, but is still trading at a price 48% lower than that at which it was merged into the SPAC in 2021, the period of the corona epidemic and the peak of enthusiasm for the biomed market.

Alpha Tau has developed an innovative technology that uses alpha radiation, which is different from existing radiation for cancer treatment and may be more targeted at the tumor. The development of the company was born at Tel Aviv University (hence the name of the company – Tel Aviv University) and the company went through many upheavals and almost closed down, until it was found by Uzi Sofer, former CEO of the Brainsoy company.

Sofer decided to take the issue as a challenge, was appointed CEO of the company, made significant changes to its capital structure, gave it its current name and set it off on a new path. The company raised approximately $80 million from private funds, until in 2021 it carried out the merger as mentioned.

These days she is starting an experiment with brain cancer. She is in further trials in various types of cancer. In September, a pancreatic cancer trial began, in which the company will treat 30 cancer patients who were found unsuitable for surgery. In the first quarter of 2026, it is expected to receive results from a multicenter trial in a type of skin cancer (squamous cell carcinoma).

Still no income

By the end of the year, it wishes to submit its technology for marketing approval specifically in Japan, for the treatment of head and neck cancer, following a trial conducted in Japan for this indication. If approved, it will be the company’s first commercial product. She has several more trials in progress. In other words, the investors expect many announcements on behalf of the company in the coming year, and hope that they will be announcements of liabilities. This expectation of news is probably one of the factors pushing the stock up, along with the possibility that the technology will be recognized by one of the leading companies in the field and a strategic deal will be signed.

In preparation for the possibility that the product will be approved following one of the tests in the next two years, Alpha Tau has already applied for a license to handle radioactive materials, and in October the license was received for the company’s production facility in New Hampshire, where approximately 2 million dollars were invested.

Alpha Tau has no revenue yet. The company’s coffers had 75.9 million dollars as of the end of the third quarter.